Publication date: Jul 15, 2025
The safety of XBB. 1.5-containing COVID-19 mRNA vaccines warrants investigation. We assessed the relative risk of 15 adverse events following the XBB. 1.5 vaccination using a self-controlled case series study design with data from the National COVID Cohort Collaborative (N3C) from September 11, 2023, to June 1, 2024 in the USA. Based on a baseline population of 244,494 patients, adverse events included Guillain-BarrcE9 syndrome, seizure, non-hemorrhagic stroke and transient ischemic attack, hemorrhagic stroke, narcolepsy or cataplexy, anaphylaxis, acute myocardial infarction, myo/pericarditis, coagulopathy, multisystem inflammatory syndrome, Bell’s palsy, transverse myelitis, appendicitis, pulmonary embolism, and encephalitis. We found an association between vaccination and anaphylaxis (IRR [95% CI]: day 0-17. 35 [9. 32-30. 03], day 1-9. 35 [5. 12-15. 95], day 2-6. 20 [3. 40-10. 57],
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | syndrome |
| disease | MESH | seizure |
| disease | MESH | hemorrhagic stroke |
| disease | MESH | transient ischemic attack |
| disease | MESH | narcolepsy |
| disease | MESH | cataplexy |
| disease | MESH | anaphylaxis |
| disease | MESH | pericarditis |
| disease | MESH | Bell’s palsy |
| disease | MESH | transverse myelitis |
| disease | MESH | appendicitis |
| disease | MESH | pulmonary embolism |
| disease | MESH | encephalitis |